GLASGOW, Scotland, April 19, 2021:
Sure Retractors Ltd, a medical devices company based in the UK, has engaged Concentra Capital Group, LLC to help raise equity capital to develop and launch the Sure Retractor product pipeline in the US.
Forbes Butterfield, CEO of SURE, said:
“We have a disruptive technology, and our aim has always been to develop our IP-protected pipeline of products to take to the US market.
As the market changes post-Covid, to more surgeries being done in the Ambulatory Surgery Centres, we believe our technology will help improve procedural efficiency, reduce overall costs and provide surgeons with surgical benefits in the OR.
We look forward to working with Concentra and leveraging their experience in the US to help us achieve our goals”.
Joe Adipietro, Managing Partner of Concentra, commented:
“SURE has proven the concept of single-use sterile radiolucent retractors with positive feedback from a number of surgeons in the US and UK.
We are very pleased and excited to have the opportunity to assist SURE with its disruptive retractor technology and its launch in the US market”.
SURE is a medical devices company that has developed an industry-disruptive retractor for spinal surgery. The device is made of a special polymer material which is lightweight, strong and radiolucent, resulting in lower X-Ray exposure for the surgical team.
SURE’s retractor is single-use which eliminates the risk of cross-contamination and costs significantly less than the comparable metal retractors on the market today. SURE has filed patents for its technology around the world.
Concentra Capital Group is a client-focused investment banking firm that assists privately held businesses with capital raising and strategic M&A transactions.